BOSTON & SAN FRANCISCO--(BUSINESS WIRE)-- Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced the company has been selected as the winner of the Digital Health Innovation Award in the 2020 MedTech Breakthrough Awards Program. MedTech Breakthrough is an independent market intelligence organization that recognizes top companies, technologies, and products in the global health and medical technology market. The award program received over 3,750 nominations from around the world this year.

“We are honored to be recognized by MedTech Breakthrough for our digital health innovation,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics. This award reinforces Pear’s leadership in creating the new therapeutic class and bringing to market the first three FDA-authorized PDTs. PDTs hold tremendous potential to provide better quality of care, increase access to care, and help redefine standard of care for the treatment of serious disease for patients around the world.”

Pear is pioneering a completely novel approach to treating disease by developing and delivering clinically validated software-based therapeutics. PDTs directly treat diseases, demonstrate safety and efficacy in randomized clinical trials, receive labeled claims from FDA, and are available only by prescription. Pear’s leadership in PDTs is demonstrated by its three FDA-authorized products, reSET®, reSET-O® and Somryst™.

The MedTech Breakthrough organization performs one the deepest evaluations of the digital health and medical technology industry landscape, with the aim of selecting and highlighting innovative solutions and companies that address a true need, solve a complex or critical problem, or seize an opportunity and create or revolutionize a new market or industry. All award nominations were evaluated by an independent panel of experts within the MedTech industry, including medical professionals, journalists, analysts, and technology executives.

About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas. Pear’s lead product, reSET®, for the treatment of Substance Use Disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of Opioid Use Disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™ for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005586/en/